Abstract 203P
Background
Ovarian functions in premenopausal breast cancer patients are frequently affected due to the applied chemotherapy regimen. In this study, we aimed to evaluate the ovarian functions after chemotherapy by assessing the AMH, the number of antral follicle and the volume of ovaries in the premenopausal patients with breast cancer.
Methods
Fifty-one premenopausal operable breast cancer patients who were given adjuvant and neoadjuvant chemotherapy were included in our study. We planned to evaluate the change of serum AMH levels throughout the timeline of the study and ovarian volume-antral follicle numbers measured by transvaginal ultrasonography. First measurements were performed before chemotherapy and repeated in every following 3 months for one-year follow-up period.
Results
Interim third month and initial results of 31 patients were evaluated. Median age: 39 (range: 23-48). The results of 31 patients' 3rd AMH results and the measurements of ovarian volumes and antral follicle numbers of 28 patients were recorded prospectively from database. Initial AMH levels and 3rd follow-up AMH levels were compared revealing statistically significant decrease (p = 0.000). When pre- and post-chemotherapy measurements were compared right and left ovary volumes and antral follicle numbers demonstrated statistically significant decrease after chemotherapy (p = 0.000).
Conclusions
Preliminary data of this study showed that 3rd month AMH levels, antral follicle numbers and ovarian volumes were significantly lower in contrast to pretreatment measurements. By the end of study period we aimed to evaluate the effects of different chemotherapy regimens on ovarian function and predictive strength of utilized markers for evaluation of ovarian function.
Clinical trial identification
Legal entity responsible for the study
Istanbul Bilim University Medical Faculty
Funding
None
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract